Huifeng Bio-Pharmaceutical Technology, Inc.
US Elections Calendar ~ Pervez Musharraf ~ Iftikhar Muhammad Chaudhry ~ Other International News
Home / International News / Press Releases / April 30, 2008
Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008

Top News

Karnataka High Court orders Ramoji Rao to appear in Ballari Court

At least 32 persons including six security men injured in grenade attack in J-K

Menon meets IAEA chief ahead of briefing to Board

TomKats daughter Suri is too old to drink from bottle

Wipro posts Rs 908 Crore net

China prepares to greet Olymipics visitors with a warm Hello

Now, a painless microneedle that mimics a mosquitos bite

Rise in research journals online causing researchers to cite fewer, newer papers

Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008

XI'AN, China, April 30 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced that it will release financial results for their first quarter ended March 31 on Thursday, May 15, 2008, after the US markets close. Huifeng's earnings release and related materials will be available on the investor's page of its website, http://www.hfgb.cn .

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

    For more information, please contact:

     Dan Carlson, Primary Capital LLC
     Tel:   +1-415-460-1165
     Email: DCarlson@PrimaryLLC.com

SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.

International News / Press Release source: PR Newswire
Copyright PR Newswire. All Rights Reserved.

International Business News / Press Releases

/C O R R E C T I O N -- China Sky One Medical, Inc./
PR Newswire

Cohen & Steers Funds Quarterly Data Now Available
PR Newswire

Galderma Announces Approval for Differin(R) Gel 0.1% in Japan
PR Newswire

Back-to-Back Top 10 Finishes for Indy Racing League Rookie Mario Moraes
PR Newswire

MutualFirst Announces Increased Second Quarter 2008 Earnings
PR Newswire

International Health News / Press Releases

/C O R R E C T I O N -- China Sky One Medical, Inc./
PR Newswire

Galderma Announces Approval for Differin(R) Gel 0.1% in Japan
PR Newswire

Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
PR Newswire

Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
PR Newswire

Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
PR Newswire

International Medical News / Press Releases

/C O R R E C T I O N -- China Sky One Medical, Inc./
PR Newswire

Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
PR Newswire

Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
PR Newswire

Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
PR Newswire

Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
PR Newswire